Clinical Trial â Zoster Eye Disease Study â Shingles
This is a multi-center, randomized, double-masked, clinical trial, led by New York University School of Medicine.
The objective is to determine whether prolonged suppressive oral antiviral treatment reduces complications of HZO (shingles in the eye). The result is helpful to improving clinical outcomes in this common disease.
| Study Type : | Interventional  (Clinical Trial) |
| Estimated Enrollment : | 1050 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | Long-term Suppressive Valacyclovir Treatment for Herpes Zoster Ophthalmicus |
| Actual Study Start Date : | August 23, 2017 |
| Estimated Primary Completion Date : | December 31, 2020 |
| Estimated Study Completion Date : | December 31, 2020 |
Contacts
| United States, Alabama | |
| University of Alabama at Birmingham | Recruiting |
| Birmingham, Alabama, United States, 35233 | |
| Contact: Lindsay Gregg   205-488-0777   lindsaygregg@uabmc.edu | |
| Principal Investigator: Priscilla Fowler, MD | |
| ClinicalTrials.gov Identifier: | NCT03134196 |
For enrollment please visit www.clinicaltrials.gov.
* The Content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.